Advertisement

Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 600x60px
Document › Details

Medigene AG. (10/28/11). "Press Release: MediGene Receives Authorization for the Clinical Formulation Study of RhuDex". Martinsried.

Region Region United Kingdom (GB)
Organisation Organisation Medigene AG (MDG1, Frankfurt, Prime Standard)
  Group Medigene (Group)
Products Product RhuDex®
  Product 2 oral drug delivery technology
Persons Person Mathias, Frank (Rentschler 201604– CEO before Medigene + Amgen GmbH + Servier DE + Hoechst)
  Person 2 Hofmann, Julia (Medigene 201604 PR/IR)
     


MediGene AG (Frankfurt: MDG, Prime Standard) announced today that the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) granted the authorization of the planned clinical formulation study of RhuDex®, a drug candidate being developed for the treatment of rheumatoid arthritis. The objective of the RapidFACTTM trial (Rapid Formulation Development and Clinical Testing) is to determine an optimized formulation for chronic treatment. Upon the initiation of the planned study, MediGene will provide additional details on the design and duration of the trial.

Dr. Frank Mathias, MediGene's CEO, commented: "Preliminary formulations of RhuDex® permitted initial clinical trials of the drug candidate. For the long-term development and subsequent marketability of the product, however, we seek an improved formulation and dosage form of RhuDex® to facilitate a therapeutically ideal release of the active ingredient as well as patient-friendly dosing. We are delighted to be able to continue the clinical development of RhuDex® with an optimized product candidate."

RhuDex®: RhuDex® is an oral therapy being developed as a disease-modifying drug for the treatment of rheumatoid arthritis targeting the successful group of Disease-Modifying Antirheumatic Drugs (DMARDs). RhuDex® is an orally administered CD80 antagonist that blocks undesired activation of T-cells and has an immunomodulating and anti-inflammatory effects. In a Phase IIa trial in 29 patients, RhuDex® demonstrated first indications of biological activity.

This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the forward-looking statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene® and RhuDex® are registered trademarks of MediGene AG. These trademarks may be owned or licensed in select locations only.

- ends -

MediGene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered in Martinsried/Munich, Germany. MediGene is the first German biotech company to have revenues from marketed products. It has various drug candidates in clinical development and possesses innovative platform technologies. MediGene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases.

Contact MediGene AG
Julia Hofmann, Kerstin Langlotz
Investor & Public Relations
Tel.: +49 - 89 - 85 65 - 33 01
Fax: +49 - 89 - 85 65 - 29 20
Email: investor@medigene.com

   
Record changed: 2016-04-10

Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px

More documents for Medigene (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wpq




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 Barcelona 120x240px wpssy Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px